Therefore, it is possible that combining QSM and assessment of NfL could provide a biomarker for PD, MSA, and PSP with high diagnostic accuracy as well as better sensitivity and specificity. This evidence concerns the gene NEFL and supranuclear palsy, progressive, 1.